Steve Bryson, PhD,  science writer—

Long-term Trikafta treatment led to sustained improvements in CFTR function and reduced lung symptoms in children, ages 6-11, with cystic fibrosis (CF), according to almost three years of interim data from an open-label extension (OLE) study. There were no signs of lung function decline during the 3.5-year treatment…

Sionna Therapeutics’ second-generation molecules, combined with standard CFTR modulators, fully restored the production and function of the CFTR protein with the most common mutation that causes cystic fibrosis (CF), according to preclinical data. The Series 2 molecules, SION-719 and SION-451, are undergoing investigational new drug (IND) enabling…

A high degree of genetic diversity was found among strains of Pseudomonas aeruginosa bacteria initially infecting the lungs of people with cystic fibrosis (CF), a study reports. Over a seven-year follow-up, the majority of CF patients experience a recurrence of the bacteria, with one-third of those being infected…

All the cystic fibrosis (CF) patients participating in the Phase 2 portion of a clinical trial have been dosed with BX004, an inhaled virus-based therapy for chronic Pseudomonas aeruginosa bacterial infections of the lungs. Data from the first part of the Phase 1b/2a study (NCT05010577) showed the…

Journaling — writing thoughts and feelings to understand them more clearly — improved the mental health of adolescents with cystic fibrosis, results from a feasibility study reveal. All teens with cystic fibrosis (CF) who completed post-therapy surveys said journaling helped them express their feelings and recommended others with CF…

More than half of the infections caused by the Burkholderia cepacia complex (BCC), a bacteria known to cause serious complications in people with cystic fibrosis (CF), were successfully eradicated, a 20-year study reported. Despite some CF patients testing negative following initial treatment for more than two years, however, subsequent…

Oral red ginseng extract eased the signs of cystic fibrosis (CF) in the lungs of rats, a study reports. The extract’s effect was thought to enhance the activity of TMEM16A, a chloride transport protein similar to CFTR, which is defective in CF. The treatment improved chloride flow and reduced…

Telemedicine programs for managing cystic fibrosis (CF) were at least as effective as standard in-clinic care, according to a review study. Adhering to treatment regimens and patient satisfaction with telemedicine improved significantly across most studies examined, and most participants favored continuing with telemedicine. The review study, “…

LasB, an enzyme that promotes Pseudomonas aeruginosa infections in the lungs of people with cystic fibrosis (CF), is significantly more active in the early stages of infection with the bacteria, known more simply as P. aeruginosa, a study revealed. These findings suggest that therapies targeting LasB may be…

A newly identified therapeutic target showed a potential to enhance the effectiveness of antibiotics against resistant Mycobacterium abscessus (Mabs) lung infection, a damaging complication in people with cystic fibrosis (CF), researchers report. Experiments using human airway organoids derived from CF patients also accurately reflected many features seen in their…